Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ FuelCell Energy Block System Receives 99.873% PJM Capacity Rating as Demand Grows for On-Site Power (GlobeNewswire EN) +++ FUELCELL Aktie +3,48%

GERON Aktie

 >GERON Aktienkurs 
1.093 EUR    -0.6%    (TradegateBSX)
Ask: 1.125 EUR / 0 Stück
Bid: 1.092 EUR / 0 Stück
Tagesumsatz: 1520 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
GERON Aktie über LYNX handeln
>GERON Performance
1 Woche: -0,4%
1 Monat: -4,2%
3 Monate: -14,7%
6 Monate: -20,1%
1 Jahr: -1,1%
laufendes Jahr: -8,6%
>GERON Aktie
Name:  GERON CORP. (DEL.) DL-001
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US3741631036 / 902213
Symbol/ Ticker:  GON (Frankfurt) / GERN (NASDAQ)
Kürzel:  FRA:GON, ETR:GON, GON:GR, NASDAQ:GERN
Index:  -
Profil:  Geron Corporation is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for blood cancers and related hematologic disorders. Its lead product is RYTELO (imetelstat), a telomerase inhibitor used in the tre..
>Volltext..
Marktkapitalisierung:  686.61 Mio. EUR
Unternehmenswert:  642.04 Mio. EUR
Umsatz:  182.18 Mio. EUR
EBITDA:  -32.35 Mio. EUR
Nettogewinn:  -62.25 Mio. EUR
Gewinn je Aktie:  -0.09 EUR
Schulden:  224.22 Mio. EUR
Liquide Mittel:  57.47 Mio. EUR
Operativer Cashflow:  -101.86 Mio. EUR
Bargeldquote:  4.3
Umsatzwachstum:  28.3%
Gewinnwachstum:  18.08%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  -
Suchwörter:  GERON
Letzte Datenerhebung:  21.10.26
>GERON Kennzahlen
Aktien/ Unternehmen:
Aktien: 642.47 Mio. St.
Frei handelbar: 98.57%
Rückkaufquote: -0.61%
Mitarbeiter: 258
Umsatz/Mitarb.: 0.63 Mio. EUR
Analysten:
Analystenrating: Strong buy
Kursziel: 242.06%
Bewertung:
KGV: -
KGV lG: -
KUV: 3.89
KBV: 3.72
PEG-Ratio: -
EV/EBITDA: -
Rentabilität:
Bruttomarge: 96.45%
Gewinnmarge: -34.17%
Operative Marge: -18.36%
Managementeffizenz:
Gesamtkaprendite: -13.01%
Eigenkaprendite: -29.24%
>GERON Peer Group
Gesundheit, Onkologie/ Krebs- Behandlung
 
21.10.26 - 14:01
Geron Plans to Announce Third Quarter 2026 Financial Results on November 4, 2026 (GlobeNewswire EN)
 
FOSTER CITY, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood cancer, today announced that it will release its third quarter 2026 financial results and business highlights before the market opens on Wednesday, November 4, 2026, via press release, which will be available on the Investors section of the Company's website. Geron will host a conference call and webcast at 8:00 a.m. Eastern Time....
19.10.26 - 22:02
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire EN)
 
FOSTER CITY, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood cancer, today reported that, effective October 16, 2026, it granted stock options to purchase an aggregate of 570,000 shares of common stock to three newly hired employees as an inducement material to such employees' acceptance of employment with Geron....
13.10.26 - 20:54
Did Geron Corporation Insiders Breach their Fiduciary Duties to Shareholders? (PR Newswire)
 
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses. Shareholders should contact the......
12.10.26 - 14:06
Geron Corporation Announces Oral Presentations Highlighting Imetelstat at International Hematology Congresses in Europe and Asia (GlobeNewswire EN)
 
Presentations feature real-world experience and clinical evidence in lower-risk MDS, underscoring growing global scientific engagement with imetelstat ...
07.10.26 - 08:00
Geron-Aktie mit -98% – große Chance oder großes Risiko? (Sharedeals)
 
Die Geron-Aktie notiert aktuell bei 1,21 US$ und befindet sich erneut an einer langfristig wichtigen Unterstützungszone. Seit dem Zwischenhoch von 2024 hat der Biotech-Titel rund drei Viertel seines Wertes verloren. Gleichzeitig drehen RSI und MACD wieder nach unten. Droht nun der Bruch der psychologisch wichtigen Marke von 1,00 US$? Chartanalyse zur Geron-Aktie Die Geron-Aktie bewegt […] The post Geron-Aktie mit -98% – große Chance oder großes Risiko? first appeared on sharedeals.de....
26.09.26 - 04:42
Did Geron Corporation Insiders Breach their Fiduciary Duties to Shareholders? (PR Newswire)
 
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses. Shareholders should contact the......
26.09.26 - 04:03
Geron Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Geron Corporation - GERN (PR Newswire)
 
NEW YORK and NEW ORLEANS, Sept. 25, 2026 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into Geron Corporation ("Geron" or the "Company")......
09.09.26 - 15:12
Geron auf Cantor-Gesundheitskonferenz: RYTELO-Wachstum und der Weg zur Profitabilität (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
02.09.26 - 22:06
Did Geron Corporation Insiders Breach their Fiduciary Duties to Shareholders? (PR Newswire)
 
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses. Shareholders should contact the......
02.09.26 - 19:39
Kuehn Law Encourages Investors of Geron Corporation to Contact Law Firm (PR Newswire)
 
NEW YORK, Sept. 2, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Geron Corporation (NASDAQ: GERN) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Geron......
12.08.26 - 12:36
Swedish PM Calls Spanish Illegal Immigrant Amnesty ′Very Bad Idea′ (ZeroHedge)
 
Swedish PM Calls Spanish Illegal Immigrant Amnesty 'Very Bad Idea' Authored by Guy Birchall via The Epoch Times, Swedish Prime Minister Ulf Kristersson has called the Spanish government's amnesty for illegal immigrants a "very bad idea," warning that it could spark another migrant crisis akin to the one that beset the continent in 2015. Swedish Prime Minister Ulf Kristersson in Brussels on Dec. 19, 2024. Johanna Geron/Reuters The center-right politician, who is running for reelection next month, told the Financial Times in an interview published on Aug. 11 that the Spanish amnesty for more than a million illegal immigrants had caused a "pretty big outcry" at the last summit of EU leaders. Spanish Prime Minister Pedro Sánchez's government granted a royal decree on April 14, launching the regularization of people living illegally in the country. The proposal was first presented on Jan. 27 to allow about 500,000 illegal immigrants already living and working in Spain to ob...
06.08.26 - 06:36
Geron (GERN) Q2 2026 Earnings Call Transcript (Fool)
 
RYTELO demand grew 5% as prescribing accounts hit 1,575 since launch....
05.08.26 - 17:57
Geron adds a record 16% as Rytelo drives Q2 revenue beat (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
05.08.26 - 14:54
Geron übertrifft Umsatzprognose in Q2 2026, schreibt aber weiterhin Verluste (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
05.08.26 - 13:12
Geron GAAP EPS of -$0.02 misses by $0.01, revenue of $57.48M beats by $2.1M (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
04.08.26 - 17:45
Geron Q2 2026 Earnings Preview (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
22.07.26 - 22:03
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire EN)
 
FOSTER CITY, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective July 17, 2026, it granted stock options to purchase an aggregate of 202,500 shares of common stock to five newly hired employees as an inducement material to such employees' acceptance of employment with Geron....
22.07.26 - 13:03
Geron Plans to Announce Second Quarter 2026 Financial Results on August 5, 2026 (GlobeNewswire EN)
 
FOSTER CITY, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that it will release its second quarter 2026 financial results and business highlights before the market opens on Wednesday, August 5, 2026, via press release, which will be available on the Investors and Media section of the Company's website. Geron will host a conference call and webcast at 8:00 a.m. Eastern Time....
14.07.26 - 22:30
Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire EN)
 
FOSTER CITY, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it granted an equity award in the form of a stock option to purchase 1,700,000 shares of Geron common stock to Chinmaya Rath, Geron's new Chief Business Officer, as an inducement material to his acceptance of employment with Geron....
13.07.26 - 14:03
Geron Announces Appointment of Chinmaya Rath as Chief Business Officer (GlobeNewswire EN)
 
Mr. Rath brings senior leadership experience in business development across a range of biopharmaceutical companies Mr. Rath brings senior leadership experience in business development across a range of biopharmaceutical companies...
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Niemand ist so glücklich oder unglücklich, wie er sich einbildet. - François VI. Duc de La Rochefoucauld
>Aktienauflistung | >Aktienscreener | >Aktienkennzahlen | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!